OverviewSuggest Edit

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Its mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. 

HQCambridge, US
Employee Ratings4.4

Latest Updates

Employees (est.) (Feb 2020)675(+6%)
Job Openings13
Revenue (FY, 2019)$6.9 M(-92%)
Share Price (Oct 2020)$63.9
Cybersecurity ratingBMore

Key People/Management at Sage Therapeutics

Jeffrey Jonas

Jeffrey Jonas

Jeff Jonas

Jeff Jonas

Chief Executive Officer
Mike Cloonan

Mike Cloonan

Chief Business Officer
Stephen Kanes

Stephen Kanes

Chief Medical Officer
Jim Doherty

Jim Doherty

Chief Research Officer
Kimi Iguchi

Kimi Iguchi

Chief Financial Officer
Show more

Sage Therapeutics Office Locations

Sage Therapeutics has offices in Cambridge and Raleigh
Cambridge, US (HQ)
215 First St
Raleigh, US
7751 Brier Creek Pkwy
Show all (2)

Sage Therapeutics Financials and Metrics

Sage Therapeutics Revenue

Sage Therapeutics's revenue was reported to be $6.87 m in FY, 2019

Revenue (Q2, 2020)


Net income (Q2, 2020)


EBIT (Q2, 2020)


Market capitalization (14-Oct-2020)


Closing stock price (14-Oct-2020)


Cash (30-Jun-2020)



Sage Therapeutics's current market capitalization is $3.3 b.
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



General and administrative expense


R&D expense


Operating expense total

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Accounts Receivable


Prepaid Expenses



USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Accounts Receivable


Prepaid Expenses


Current Assets

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income


Depreciation and Amortization




Accounts Payable

USDQ2, 2014

Financial Leverage

-1.2 x
Show all financial metrics

Sage Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Sage Therapeutics Online and Social Media Presence

Embed Graph

Sage Therapeutics News and Updates

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened

SAN FRANCISCO, Dec. 10, 2019 /PRNewswire/ -- Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who have suffered losses in excess of $100,000 on purchases prior to December 5, 2019 to submit their losses now to learn if they qualify to recover compensable damages. The...

Sage Therapeutics craters 64% after failing a key trial for its depression drug

Shares of Sage Therapeutics, a Cambridge-based pharmaceutical company, cratered almost 64% on Thursday morning.  The crash came after the drugmaker — which focuses on brain disorders — reported disappointing study results for a key depression treatment.  The trial showed that patients who took the…

The Ratings Game: Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout

Shares of Sage Therapeutics Inc. rose 3% Wednesday morning after the company’s announcement Tuesday evening that the Food and Drug Administration had approved its drug for the treatment of postpartum depression.

Sage Therapeutics stock rises after FDA approves first postpartum depression drug Zulresso

Zulresso is an IV injection used to treat the sometimes life-threatening condition of postpartum depression, which is a major depressive episode that occurs following or leading up to childbirth.

Postpartum Depression Drug Market is Forecasted to Witness a Thriving Growth By 2026 With Top Key Players Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Mylan N.V., Shionogi & Co., Ltd.

Increasing research activities for the treatment of PPD is expected to propel the growth of the postpartum depression drug market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Sage Therapeutics shares halted ahead of regulatory meeting on post-partum treatment

Sage Therapeutics Inc. said Friday its stock has been halted premarket ahead of a joint meeting of the U.S. Food and Drug Administration Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to discuss its Zulresso treatment for postpartum depression. T…
Show more

Sage Therapeutics Frequently Asked Questions

  • When was Sage Therapeutics founded?

    Sage Therapeutics was founded in 2010.

  • Who are Sage Therapeutics key executives?

    Sage Therapeutics's key executives are Jeffrey Jonas, Jeff Jonas and Mike Cloonan.

  • How many employees does Sage Therapeutics have?

    Sage Therapeutics has 675 employees.

  • What is Sage Therapeutics revenue?

    Latest Sage Therapeutics annual revenue is $6.9 m.

  • What is Sage Therapeutics revenue per employee?

    Latest Sage Therapeutics revenue per employee is $10.2 k.

  • Who are Sage Therapeutics competitors?

    Competitors of Sage Therapeutics include Roivant Sciences, Qu Biologics and Sequani.

  • Where is Sage Therapeutics headquarters?

    Sage Therapeutics headquarters is located at 215 First St, Cambridge.

  • Where are Sage Therapeutics offices?

    Sage Therapeutics has offices in Cambridge and Raleigh.

  • How many offices does Sage Therapeutics have?

    Sage Therapeutics has 2 offices.